HeartBeam Appoints New CMO, Director; Discloses Officer Compensation

TL;DR

HeartBeam names new CMO, adds a director, and details exec pay. #medtech #leadership

AI Summary

HeartBeam, Inc. announced on October 17, 2024, the appointment of Dr. Michael J. McGovern as Chief Medical Officer and the election of Ms. Wendy L. Johnson to its Board of Directors. The company also disclosed compensatory arrangements for certain officers, including stock options and warrants, as part of its ongoing business operations.

Why It Matters

The appointment of a new Chief Medical Officer and a board member signals potential strategic shifts or growth initiatives within HeartBeam, while the disclosure of compensation arrangements provides transparency to investors regarding executive incentives.

Risk Assessment

Risk Level: medium — Changes in key leadership and executive compensation can indicate internal shifts that may impact future performance and strategy.

Key Players & Entities

• HeartBeam, Inc. (company) — Registrant
• Dr. Michael J. McGovern (person) — Appointed Chief Medical Officer
• Ms. Wendy L. Johnson (person) — Elected to Board of Directors
• October 17, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-41060 (identifier) — SEC File Number
• 47-4881450 (identifier) — IRS Employer Identification No.
• 2118 Walsh Avenue, Suite 210 (address) — Principal executive offices
• Santa Clara, CA 95050 (address) — Principal executive offices
• 408-899-4443 (phone_number) — Registrant's phone number

FAQ

Key Financial Figures

• $400,000 — ill compensate Mr. Eno an annual fee of $400,000, which is to be paid in semi-monthly in

Filing Documents

• beat-20241017.htm (8-K) — 45KB
• heartbeambranislavvajdicem.htm (EX-10.2) — 5KB
• heartbeamrobenoemploymenta.htm (EX-10.2) — 14KB
• heartbeamceopressrelease_1.htm (EX-99.1) — 14KB
• image_0.jpg (GRAPHIC) — 17KB
• 0001628280-24-043338.txt ( ) — 280KB
• beat-20241017.xsd (EX-101.SCH) — 2KB
• beat-20241017_def.xml (EX-101.DEF) — 16KB
• beat-20241017_lab.xml (EX-101.LAB) — 28KB
• beat-20241017_pre.xml (EX-101.PRE) — 17KB
• beat-20241017_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 17, 2024, the Company issued a press release announcing the appointments. A copy of the press release is filed hereto as Exhibit 99.1 and is incorporated herein by reference. The information set forth under this Item 7.01 is furnished pursuant to Item 7.01 and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration document or other document filed by the Company.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 10.2 HeartBeam Rob Eno Employment Agreement 10.2 HeartBeam Branislav Vajdic Employment Agreement 99.1 Press Release dated October 17 , 2024

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. HeartBeam, Inc. Date: October 22, 2024 By: /s/ Timothy Cruickshank Name: Timothy Cruikshank Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR